Health Outcomes/Health Technology Assessment/Real World Evidence, Eli Lilly Japan, Kobe, Japan,
Bio-Medicines, Medicines Development Unit, Eli Lilly Japan, Kobe, Japan.
Clin Interv Aging. 2018 Oct 26;13:2179-2191. doi: 10.2147/CIA.S176289. eCollection 2018.
Patient satisfaction is an important outcome in successful osteoarthritis (OA) treatment. The aim of this study was to evaluate treatment satisfaction for medication (TSM) in people with knee OA (KOA), identify the factors predictive of treatment satisfaction, and describe the burden of illness.
This cross-sectional, patient-reported study used an Internet-based survey and analyzed responses of respondents with KOA (N=400) on characteristics including pain sites and levels (including pain ratings using the Numerical Rating Scale and Short-Form McGill Pain Questionnaire), treatment satisfaction (Global, Effectiveness, and Convenience scores) based on the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and quality of life (QoL; based on the Arthritis Impact Measurement Scale 2-Short Form). Respondents with only KOA (n=237) were compared with those having KOA and additional painful sites (KOA+; n=163). Factors predicting TSM were identified using multivariable linear regression analyses.
Respondents with KOA were more likely to report intermittent pain for 3 months or more compared with those with KOA+ (58.6% vs 48.5%, respectively; =0.044), while those with KOA+ were more likely to report consistent pain for 3 months or more (=0.022). Respondents with KOA+ also had more difficulty due to their knee pain while sleeping (=0.022) and resting (=0.015). Reported TSM did not differ significantly across KOA vs KOA+ groups, with both groups reporting low satisfaction; all domains of QoL were worse for those with KOA+. Knee pain reduction by medication predicted higher satisfaction across domains, while lower pre-medication pain and post-medication pain matching expectations predicted higher TSQM-9 Global and Effectiveness scores.
Medication treatment satisfaction rates were low among Japanese respondents with KOA. Given that lower pain, greater pain reduction post-medication, and meeting pain management expectations were predictive of higher satisfaction, treatment strategies that can better address pain may prove beneficial for overall patient satisfaction.
患者满意度是成功治疗骨关节炎(OA)的重要结果。本研究旨在评估膝骨关节炎(KOA)患者对药物治疗的满意度(TSM),确定治疗满意度的预测因素,并描述疾病负担。
这是一项横断面、患者报告的研究,使用基于互联网的调查,并分析了 400 名 KOA 患者的特征,包括疼痛部位和程度(包括使用数字评分量表和简化 McGill 疼痛问卷的疼痛评分)、基于药物治疗满意度问卷(TSQM-9)的总体满意度、疗效满意度和便利性满意度评分,以及基于关节炎影响测量量表 2-短表的生活质量(QoL)。仅 KOA 患者(n=237)与 KOA 合并其他疼痛部位的患者(KOA+;n=163)进行比较。使用多变量线性回归分析确定预测 TSM 的因素。
与 KOA+患者相比,KOA 患者更有可能报告持续 3 个月或更长时间的间歇性疼痛(分别为 58.6%和 48.5%;=0.044),而 KOA+患者更有可能报告持续 3 个月或更长时间的持续疼痛(=0.022)。KOA+患者在睡眠和休息时因膝关节疼痛而感到困难的情况也更为严重(=0.022 和=0.015)。KOA 与 KOA+组之间的 TSM 报告没有显著差异,两组的满意度均较低;KOA 患者的所有 QoL 领域均较差。药物治疗后膝关节疼痛减轻可预测各领域满意度更高,而较低的治疗前疼痛和治疗后疼痛与预期相符可预测 TSQM-9 总体和疗效评分更高。
日本 KOA 患者的药物治疗满意度较低。鉴于较低的疼痛、药物治疗后更大的疼痛缓解以及符合疼痛管理预期与更高的满意度相关,能够更好地控制疼痛的治疗策略可能对整体患者满意度有益。